Vedolizumab

Summary

Vedolizumab (CHEMBL1743087) is an approved antibody (ATC L04AG05); indicated across 13 conditions including crohn disease and ulcerative colitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: L04AG05
• Indications: 13 conditions
• Clinical trials: 100

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1743087
Name	Vedolizumab
Type	Antibody
Max phase	4
ATC	L04AG05

Also known as: Entyvio, LDP-02, LDP02, MLN-0002, MLN-02, MLN0002, MLN02, Vedolizumab, VEDOLIZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	integrin α4β7	Antagonist	8.27

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

13 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Crohn disease	4	MONDO:0005011	EFO:0000384
ulcerative colitis	4	MONDO:0005101	EFO:0000729
pouchitis	3	MONDO:0005312	EFO:0003921
celiac disease	2	MONDO:0005130	EFO:0001060
HIV infectious disease	2	MONDO:0005109	EFO:0000764
colitis	2	MONDO:0005292	EFO:0003872
salivary gland cancer	2	MONDO:0004669	MONDO:0000521
neoplasm	2	MONDO:0005070	MONDO:0004992
melanoma	1	MONDO:0005105	EFO:0000756
inflammatory bowel disease	1	MONDO:0005265	EFO:0003767
type 1 diabetes mellitus	0	MONDO:0005147	MONDO:0005147

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 100.

Phase distribution

Phase	Trials
PHASE4	26
Not specified	24
PHASE3	19
PHASE2	18
PHASE1	6
PHASE1/PHASE2	3
EARLY_PHASE1	3
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05481619	PHASE4	RECRUITING	Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis
NCT06045754	PHASE4	RECRUITING	A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn’s Disease
NCT06095128	PHASE4	RECRUITING	A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
NCT06180382	PHASE4	RECRUITING	Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn’s Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.
NCT06257706	PHASE4	RECRUITING	VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn’s Disease
NCT06584162	PHASE4	RECRUITING	Subcutaneous Interval Lengthening of Vedolizumab for Economic Research
NCT06609447	PHASE4	RECRUITING	The Efficacy and Safety of Combining Probiotic VSL#3 With Vedolizumab for the Treatment of Moderate Ulcerative Colitis
NCT02324699	PHASE4	TERMINATED	Corticosteroids With Vedolizumab in Crohn’s Disease
NCT02559713	PHASE4	COMPLETED	Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn’s Disease
NCT02630966	PHASE4	COMPLETED	Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn’s Disease
NCT02646657	PHASE4	COMPLETED	An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis
NCT02646683	PHASE4	COMPLETED	A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn’s Disease: the LOVE-CD Study
NCT02743806	PHASE4	TERMINATED	Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn’s Disease
NCT02760615	PHASE4	WITHDRAWN	Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
NCT02764762	PHASE4	COMPLETED	Triple Combination Therapy in High Risk Crohn’s Disease (CD)
NCT02768532	PHASE4	TERMINATED	Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn’s Disease
NCT02790138	PHASE4	COMPLETED	A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis
NCT02820493	PHASE4	WITHDRAWN	Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF
NCT03237260	PHASE4	WITHDRAWN	An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis
NCT03629379	PHASE4	COMPLETED	Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
NCT03679546	PHASE4	COMPLETED	EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis
NCT04006080	PHASE4	UNKNOWN	Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis
NCT05205603	PHASE4	COMPLETED	Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis
NCT06066840	PHASE4	UNKNOWN	Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement
NCT06626165	PHASE4	COMPLETED	Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic Mucosa
NCT07398586	PHASE4	COMPLETED	The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative Colitis
NCT04738942	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn’s Disease
NCT05515029	PHASE3	ACTIVE_NOT_RECRUITING	Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
NCT06227910	PHASE3	RECRUITING	A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn’s Disease
NCT06337695	PHASE2/PHASE3	NOT_YET_RECRUITING	VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer
NCT06443502	PHASE3	RECRUITING	A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
NCT06880744	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT00783692	PHASE3	COMPLETED	Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn’s Disease
NCT00783718	PHASE3	COMPLETED	Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
NCT00790933	PHASE3	COMPLETED	An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn’s Disease
NCT01224171	PHASE3	COMPLETED	Study of Vedolizumab in Patients With Moderate to Severe Crohn’s Disease
NCT02038920	PHASE3	COMPLETED	Phase III Study of MLN0002 (300 mg) in Treatment of Crohn’s Disease
NCT02039505	PHASE3	COMPLETED	Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
NCT02425111	PHASE3	COMPLETED	Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn’s Disease
NCT02497469	PHASE3	COMPLETED	An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).